These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7226932)

  • 21. Effects of disopyramide phosphate on ventricular arrhythmias in experimental myocardial infarction.
    Kus T; Sasyniuk BI
    J Pharmacol Exp Ther; 1976 Mar; 196(3):665-75. PubMed ID: 1263118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards.
    Zainal N; Carmichael DJ; Griffiths JW; Besterman EM; Kidner PH; Gillham AD; Summers GD
    Lancet; 1977 Oct; 2(8044):887-9. PubMed ID: 72237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of disopyramide and aprindine on arrhythmias after acute myocardial infarction.
    Pouleur H; Chaudron JM; Reyns P
    Eur J Cardiol; 1977 Jul; 5(5):397-404. PubMed ID: 330168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial.
    Sbarbaro JA; Rawling DA; Fozzard HA
    Am J Cardiol; 1979 Sep; 44(3):513-20. PubMed ID: 474432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intravenously disopyramide phosphate administration for treatment of arrhythmias].
    Aquaro G; Belli R; Pavia M; Rey L; Ravera A; Possavino G; Idone P
    G Ital Cardiol; 1982; 12(7):509-19. PubMed ID: 7169147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of an anti-arrhythmic agent, disopyramide, in delayed action form ('Ritmoforine' Retard).
    Nauta IL; van de Calseyde JF
    Curr Med Res Opin; 1981; 7(4):215-26. PubMed ID: 7226872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Collapse after oral disopyramide.
    Manolas EG; Hung D; Dowling JT; Luxton M; Vohra JK; Sloman G
    Br Med J; 1979 Dec; 2(6204):1553-4. PubMed ID: 534864
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety of multiple bolus loading of intravenous disopyramide.
    Simpson RJ; Foster JR; Benge C; Baker S; Gettes LS
    Am Heart J; 1983 Sep; 106(3):505-8. PubMed ID: 6881023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction.
    Kumana CR; Rambihar VS; Tanser PH; Cairns JA; Gupta RN; Wildeman RA; Johnston M; Johnson AL; Gent M
    Br J Clin Pharmacol; 1982 Oct; 14(4):519-27. PubMed ID: 6753887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repolarization duration in patients with conduction disturbances after myocardial infarction.
    Piotrowicz K; Zareba W; McNitt S; Moss AJ
    Am J Cardiol; 2007 Jan; 99(2):163-8. PubMed ID: 17223412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quinidine effects due to disopyramide.
    Frieden J
    N Engl J Med; 1978 Apr; 298(17):975. PubMed ID: 642984
    [No Abstract]   [Full Text] [Related]  

  • 32. The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
    Deano DA; Wu D; Mautner RK; Sherman RH; Ehsani AI; Rosen KM
    Chest; 1977 May; 71(5):597-606. PubMed ID: 856558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ventricular tachyarrhythmias induced by disopyramide and other similar anti-arrhythmic drugs.
    Croft CH; Kennelly BM
    S Afr Med J; 1981 Jun; 59(24):871-3. PubMed ID: 7233313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of the antiarrhythmic action of disopyramide by digoxin.
    García-Barreto D; Groning E; González-Gómez A; Pérez A; Hernández-Cañero A; Toruncha A
    J Cardiovasc Pharmacol; 1981; 3(6):1236-42. PubMed ID: 6173523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute oral antiarrhythmic testing with disopyramide.
    García-Barreto D; Toruncha A; Gonzalez-Gomez A; Llerena L; Groning E; Hernandez-Cañero A
    Clin Cardiol; 1981; 4(6):330-5. PubMed ID: 7326884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiogenic shock and disopyramide phosphate.
    Story JR; Abdulla AM; Frank MJ
    JAMA; 1979 Aug; 242(7):654-5. PubMed ID: 449005
    [No Abstract]   [Full Text] [Related]  

  • 37. Collapse after oral administration of disopyramide.
    Manolas EG; Hunt D; Dowling JT; Luxton M; Vohra J
    Med J Aust; 1979 Jan; 1(1):20. PubMed ID: 763189
    [No Abstract]   [Full Text] [Related]  

  • 38. Some aspects of the clinical pharmacology of intravenous disopyramide after myocardial infarction.
    Hillis WS; Tweddel A; Lorimer AR; Lawrie TD
    J Int Med Res; 1976; 4(1 Suppl):74-7. PubMed ID: 1026533
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasma levels of disopyramide after administration of conventional capsules and sustained-release tablets.
    Nauta IL; van de Calseyde J; Hertzberger DP
    Curr Med Res Opin; 1983; 8(8):582-93. PubMed ID: 6653136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse effects of disopyramide (Norpace): toxic interactions with other antiarrhythmic agents.
    Ellrodt G; Singh BN
    Heart Lung; 1980; 9(3):469-74. PubMed ID: 6901519
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.